Issue link:

Contents of this Issue


Page 9 of 38

News about companies that support development of orally inhaled and nasal drug products, including regulatory approvals, new indications for OINDPs and results of clinical studies. Plus news on R&D and progress in the treatment of respiratory diseases, such as asthma and COPD. 8 August 2022 Inhalation INDUSTRY NEWS Lonza to establish new facility in Stein, CH BASEL, SWITZERLAND— Lonza has announced plans to construct a large-scale, commer- cial drug product fill and finish facility in Stein, Switzerland. Since establishing drug product develop- ment and manufacturing services in 2016, Lonza has expanded its clinical drug product offering in Basel, Stein and Visp, Switzerland and in Guangzhou, China. e investment will complete Lonza's commitment to offer integrated, end-to-end service to support cus- tomers across the entire product life cycle, explained Pierre-Alain Ruffieux, CEO, Lonza. e new facility will be located on the same campus as Lonza's current clinical drug product facility. Expected to be completed in 2026, plans include incorporation of the latest developments in sustainable con- struction and a modern approach to carbon reduction and responsi- ble energy use. H&T Presspart introduces low GWP propellant filling facility BLACKBURN, UNITED KING- DOM—H&T Presspart has announced the opening of a new laboratory at its Inhalation Prod- uct Technology Centre (IPTC), which will support development of sustainable metered dose inhal- ers (MDIs) with low global warm- ing potential (GWP) propellant. Using the new facility, Presspart can fill MDIs with a range of formulations that use both HFA 152a and HFO1234ze low GWP propellants. "This new facility will be crucial in supporting our customers to lower the environ- mental footprint and future-proof inhalation products as they look to move towards more sustainable low GWP propellants for both current and new pMDI formula- tions," said Ameet Sule, Director of H&T Presspart's IPTC. RESPIRATORY MEDICINE NEWS NIAID study shows advantages of COVID-19 nasal vaccine ROCKVILLE, MARYLAND— e United States National Insti- tute of Allergy and Infectious Diseases (NIAID) announced results of a study in laboratory mice that demonstrated a nasal vaccine for SARS-CoV-2, particularly in two doses, showed advantages compared to an intramuscular vaccine. The nasal vaccine uses the modified vaccinia virus Ankara (MVA), a licensed smallpox and monkeypox vaccine, as a vector to deliver the SARS-CoV-2 spike protein. e study was conducted by NIAID scientists and published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). Advan- tages of the nasal vaccine included: • Virus targeting: Within six hours of delivery, the nasal vac- cine was found in the nose, Trusted, Reliable Contract Development & Manufacturing R&D Services – Formulation – Scale-up – Stability – 2-100 mL vials – 2-100 mL vials Injectables – Multi-Dose – Unit Dose – Bi-Dose Multi-Dose – Unit Dose – Bi-Dose Nasal Renaissance develops and manufactures high-quality pharmaceuticals to fulfill your patients' needs. continued on page 32

Articles in this issue

Links on this page

view archives of Inhalation - INH0822